Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies is on track for continued growth with their strong performance in the MRD market, increased testing in community settings, and partnerships with pharmaceutical companies. Their plan to separate their MRD business and negotiate higher prices with health plans adds further potential for revenue and margin growth. While there are uncertainties with the separation, overall the company shows promising potential for long-term success and a BUY rating is warranted at this time.

Bears say

Adaptive Biotechnologies is facing key risks in the near future, including slower EMR integrations and increasing competition in the heme market, which could impede volume growth and strain resources for its MRD segment. Additionally, there are stock market risks and ADPT trades at a premium multiple, making it susceptible to volatility. While they have a strong position in the MRD market and continued profitability, there is uncertainty around stock reactions and future catalysts.

Adaptive Biotechnologies (ADPT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 6 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.